Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.
about
Emerging preclinical pharmacological targets for Parkinson's diseaseBiomarkers in dementia: clinical utility and new directionsThe utility of neuroimaging in the differential diagnosis of parkinsonian syndromesParkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisNeuroimaging of Parkinson's disease: Expanding views.The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3TNon-Linear EMG Parameters for Differential and Early Diagnostics of Parkinson's Disease.The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.Unbiased approaches to biomarker discovery in neurodegenerative diseasesRecent progress of imaging agents for Parkinson's disease.Design of a Multi-Pinhole Collimator for I-123 DaTscan Imaging on Dual-Headed SPECT Systems in Combination with a Fan-Beam CollimatorMini Review: linkages between essential tremor and Parkinson's disease?Creation and validation of an I-123 FP-CIT template for statistical image analysis using high-resolution SPECT for parkinsonian patients.Dopamine transporter imaging in psychogenic parkinsonism and neurodegenerative parkinsonism with psychogenic overlay: a report of three casesImaging analysis of Parkinson's disease patients using SPECT and tractographyParkinson's disease: chameleons and mimics.Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study.In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging.Establishing On-Site Reference Values for (123)I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions.Dopamine transporter single-photon emission computed tomography brain scan: A reliable way to distinguish between degenerative and drug-induced parkinsonism.Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease.Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships?Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: the N3iPD study (nigrosomal iron imaging in Parkinson's disease).Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease.Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease.Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease.Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease.Functional volumetric analysis of striatum using F-18 FP-CIT PET in patients with idiopathic Parkinson's disease and normal subjects.Interest of multi-modal imaging in bilateral lesions of basal ganglia: A case report of a post-anoxic dystonia.Relationship between [123 I]-FP-CIT SPECT and clinical progression in Parkinson's disease.Parkinsonism as a side effect of infliximab.Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user's guide.Transcranial sonography and the pocket smell test in the differential diagnosis between parkinson's disease and essential tremor.Performance evaluation of a novel brain-dedicated SPECT system.Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases.DaTscan and Parkinson's disease: DAT binding should not lead to binding decisions in clinical practice.[Differential diagnostics of Parkinson's disease with nuclear medicine procedures].
P2860
Q26764724-DD5D5F1E-8A0D-4045-840C-304A9BC0058EQ27007086-E967BEC0-0BE0-4571-A184-5A2445A2FEBBQ27025731-BDCF15E7-3E79-45D4-9B95-BA172CDB3F9BQ28384572-2C725CB3-BA9F-46A0-A975-67302DE83915Q28387732-7F4B5239-5489-4166-903B-A332030C8C6BQ28660352-8F848DAE-163E-480D-933B-04C1B136F156Q30449049-C1019BF2-6FF4-4944-AD27-A52CC4CDF5BCQ30635471-60EB89A2-4F23-496D-A38B-3F59FB76EDDBQ33879821-D732601C-7563-4075-A1EE-3F0C656BC169Q34625918-34B21FE0-B846-4D65-B0C0-96BB1D52214DQ35595426-9ED10452-C55A-40E7-BF87-34CBFCD257B3Q36894330-B24F77A1-652E-4263-B1B0-318BE831AE03Q37057709-532AE9B8-129B-4804-B6DF-3056860F78B0Q37127709-CF8C42A7-02BE-4BA1-90F6-CF803319628BQ37183540-F9E03F47-9166-4196-B2B5-82E42F0BDAC7Q37454387-4046F70D-95F9-47A4-9D20-DA451795D333Q38254117-7719845B-050B-4FE4-997F-39312642372CQ39051531-53B52939-619A-407F-8B79-A7A2079D6D12Q39758264-944E9900-F791-478D-9B21-2DD9AECD7602Q40202710-A6B8759B-B7C5-4ACE-A21A-CC09156F13E7Q41409967-D02BB622-0F6B-4021-BA6E-FF0E6D2AC7B3Q42140175-6A3A695D-5C27-4A0F-8E53-CF3FA6C48347Q42484375-FD8D770E-C678-4A66-9545-49B839444B65Q43526336-A7727AE4-52F5-4792-9E40-C357E899D656Q43831436-E71C9564-8D83-4354-BBFA-3A56E4D20850Q47096030-86DBF6EC-C5BE-48A0-8C2D-590DCBB352A4Q47653671-A8FA212A-72FA-4123-867B-F17A11585AA0Q48142962-48E4BC51-7A21-4BBE-8131-9FE6DC0E174BQ48463469-57DBFEBF-C770-4F89-ADE8-6923F2940538Q48668610-1735E7E0-7C51-489F-98E7-CD2307558EF2Q48685702-52BF62D8-27D6-4736-83EE-656B1E2BDC33Q48737264-A77DEDA5-78BE-4A35-B53B-02686A96845EQ50242405-7EE662CF-E8CB-4840-B1CB-96BD78BA89BEQ50242727-48AE189E-00DA-451C-8F5E-44C96DB932A6Q50243898-591D2048-8239-419A-8439-62B61DEE317DQ50245461-44DA9DB9-E0D5-4E30-851D-CCFABD70021DQ52680251-B394A1FA-3036-47CC-8E0F-8F2920710A7DQ52945990-EB8D4A30-2B18-442E-9B8B-CEBA66D2A2CEQ53065710-936850EA-4377-4AC0-A65E-64E0F20B50C4Q53066302-05F4F2EF-4CFC-4E16-8B68-A2AD34D0A73F
P2860
Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical utility of dopamine t ...... sis of parkinsonian syndromes.
@en
Clinical utility of dopamine transporter single photon emission CT
@nl
type
label
Clinical utility of dopamine t ...... sis of parkinsonian syndromes.
@en
Clinical utility of dopamine transporter single photon emission CT
@nl
prefLabel
Clinical utility of dopamine t ...... sis of parkinsonian syndromes.
@en
Clinical utility of dopamine transporter single photon emission CT
@nl
P2860
P921
P356
P1476
Clinical utility of dopamine t ...... sis of parkinsonian syndromes.
@en
P2093
Igor D Grachev
P2860
P304
P356
10.1136/JNNP-2012-304436
P407
P5008
P577
2013-03-13T00:00:00Z
2013-11-01T00:00:00Z